For The Better

While it makes sense why you might want to head back to work, there are several important issues to work through.

Organic revenue returned to growth as biopharmaceutical demand strengthened.

Net loss of $296M reflects U.K. tax headwinds and strategic U.S. investments.

USDC circulation hit $73.3 billion as Arc blockchain prepares for mainnet launch.

Management raised full-year guidance on strong hip and technology segment growth.

Royalty receipts surged 14% as guidance raised for second consecutive quarter.

CEO Rothblatt calls H1 2026 “one of the most consequential periods” in company history.

Market share gains offset sales decline as Perrigo completes Dermacosmetics divestiture.

Net sales hit $6.6 billion, a record, as AI and infrastructure demand drive growth.

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Net sales hit $1.77 billion with 22.2% growth across all categories.

The leading eVTOL company is making solid progress with its transportation-as-a-service business model.

With only a few weeks left in Cook’s tenure, let’s look back on how well the company has done since he took the reins.

Kinder Morgan is adding more fuel to its dividend growth engine.

The stock may be down sharply, but don’t count it out — and the lower price makes it more attractive.

It may seem like a good way to borrow, but it could easily backfire.

Huang said earlier this year that he thinks Nvidia’s Blackwell and Vera Rubin platforms will combine for $1 trillion in sales between 2025 and 2027.

The last time Intel raised equity capital, the stock went up sevenfold in a year.

The defense spending supercycle has only just begun.

History says that this cryptocurrency follows a four-year cycle.